Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II/III Study of TS-152 in Patients with Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response to Methotrexate (MTX) Therapy

Next Previous
Trial Profile

A Phase II/III Study of TS-152 in Patients with Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response to Methotrexate (MTX) Therapy

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 05 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ozoralizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms OHZORA
  • Sponsors Taisho Pharmaceutical

    • Most Recent Events

    • 13 Apr 2023 Results of post hoc analysis assessing the pharmacokinetics of the drug and its correlation with clinical efficacy (52-week results) in patients with rheumatoid arthritis from the OHZORA and NATSUZORA trials, published in the Arthritis Research and Therapy.
    • 26 Sep 2022 According to a Taisho Pharmaceutical media release, the company received approval to manufacture and market Nanozora 30mg Syringes for S.C. Injection from the Ministry of Health, Labour and Welfare for the indication of rheumatoid arthritis (RA), based on data from OHZORA and NATSUZORA study.
    • 12 Jun 2022 Primary endpoint (change in the baseline modified total Sharp score (mTSS) at Week 24) has been met, according to Results published in the Arthritis and Rheumatology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top